News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,314 Results
Type
Article (39620)
Company Profile (247)
Press Release (657447)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204127)
Career Advice (2007)
Deals (35414)
Drug Delivery (95)
Drug Development (81029)
Employer Resources (172)
FDA (16168)
Job Trends (14850)
News (345112)
Policy (32522)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2553)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49402)
ALS (86)
Alzheimer's disease (1367)
Antibody-drug conjugate (ADC) (112)
Approvals (16170)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (262)
Cancer (2083)
Cardiovascular disease (167)
Career advice (1674)
Career pathing (29)
CAR-T (143)
Cell therapy (403)
Cervical cancer (19)
Clinical research (65834)
Collaboration (794)
Compensation (508)
Complete response letters (19)
COVID-19 (2582)
CRISPR (37)
C-suite (223)
Cystic fibrosis (100)
Data (2051)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (256)
Diagnostics (6348)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86338)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (111887)
Executive appointments (693)
FDA (17352)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (718)
Gene editing (100)
Generative AI (19)
Gene therapy (285)
GLP-1 (697)
Government (4405)
Grass and pollen (4)
Guidances (51)
Healthcare (18811)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (26)
Infectious disease (2722)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (311)
IPO (16494)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (36)
Layoffs (460)
Leadership (16)
Legal (7905)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (282)
MASH (62)
Medical device (13345)
Medtech (13350)
Mergers & acquisitions (19435)
Metabolic disorders (655)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1872)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2533)
Now hiring (38)
Obesity (353)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (146)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (46)
People (57206)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20504)
Phase II (28988)
Phase III (21606)
Pipeline (1115)
Policy (130)
Postmarket research (2563)
Preclinical (8675)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (371)
Real estate (5906)
Recruiting (65)
Regulatory (22200)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2179)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (28)
United States (21996)
Vaccines (668)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Last 7 days (468)
Last 30 days (2158)
Last 365 days (32795)
2025 (9203)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31482)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29265)
2010 (27328)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37752)
Australia (6176)
California (5776)
Canada (1939)
China (489)
Colorado (253)
Connecticut (262)
Delaware (134)
Europe (81017)
Florida (860)
Georgia (202)
Idaho (57)
Illinois (513)
India (25)
Indiana (300)
Iowa (9)
Japan (149)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (856)
Massachusetts (4330)
Michigan (215)
Minnesota (378)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1659)
New Mexico (28)
New York (1650)
North Carolina (935)
North Dakota (7)
Northern California (2533)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1305)
Puerto Rico (11)
Rhode Island (30)
South America (1096)
South Carolina (20)
South Dakota (1)
Southern California (2179)
Tennessee (99)
Texas (860)
Utah (171)
Virginia (135)
Washington D.C. (59)
Washington State (530)
West Virginia (3)
Wisconsin (51)
697,314 Results for "axogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Axogen, Inc. To Host Analyst & Investor Day on March 4th
February 26, 2025
·
3 min read
Press Releases
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
February 25, 2025
·
17 min read
Press Releases
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
February 12, 2025
·
3 min read
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc. announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing.
June 24, 2024
·
6 min read
BioMidwest
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Axogen, Inc. will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on Wednesday, May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET.
May 14, 2024
·
3 min read
Business
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2024.
May 2, 2024
·
19 min read
BioMidwest
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it will celebrate the opening of its Axogen Processing Center with leaders of the Ohio community on June 12, 2024.
May 28, 2024
·
6 min read
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
Axogen, Inc. is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft ® on May 15, 2024.
May 16, 2024
·
7 min read
Press Releases
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
November 7, 2024
·
15 min read
Press Releases
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 25, 2025
·
4 min read
1 of 69,732
Next
